1 / 22

HIV Science Update: From Rome to Addis – Biomedical Prevention

HIV Science Update: From Rome to Addis – Biomedical Prevention. Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences 16 th ICASA, Addis Ababa, Ethiopia, December 6, 2011. Treatment as prevention. Population level observational data: British Columbia.

rich
Download Presentation

HIV Science Update: From Rome to Addis – Biomedical Prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences 16th ICASA, Addis Ababa, Ethiopia, December 6, 2011

  2. Treatment as prevention

  3. Population level observational data: British Columbia All receiving HIV prevention services Montaner Lancet 2010

  4. 1763 HIV discordant couples (HIV+ partner CD4 350-550) HAART delayed until CD 250 Immediate HAART 1° endpoint: HIV infection in HIV-negative partner Co- 1° endpoint: HIV disease progression in HIV+ partner HPTN 052: Impact of (earlier) ART on HIV transmission and disease progression 13 sites in 9 countries: Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, United States, Zimbabwe All receiving HIV prevention services Cohen et al NEJM 2011 and IAS 2011

  5. HPTN 052: HIV transmissions Total HIV-1 Transmission Events: 39 Linked Transmissions: 28 Unlinked or TBD Transmissions: 11 Immediate Arm: 1 Delayed Arm: 27 96% reduction in risk of HIV transmission within the partnership (95% CI 73-99%) p < 0.001

  6. Prevention of HIV acquisition in those who are HIV negative

  7. CAPRISA 004: proof of principle for microbicides CAPRISA 004: Pericoital 1% tenofovir gel • Phase 2B trial in 889 women, ages ≥18 years in South Africa • Coitally dependent: gel within 12 hours before & 12 hours after sex, max. 2 applications in 24 hours • Study population: Young women (mean age 23), unmarried Abdool Karim et al, Science July 2010

  8. HIV protection in CAPRISA 004 No HIV resistance mutations among seroconverters Q Abdool Karim et al. Science 2010

  9. iPrEx: PrEP works for MSM iPrEx: Daily oral FTC/TDF PrEP • 2499 MSM, randomized 1:1 daily oral FTC/TDF vs placebo • 11 sites (Brazil, Ecuador, Peru, South Africa, Thailand, US) • 70% from Andean sites • Young high risk MSM: • 50% <25 yrs • Median 18 partners in 12 wks prior to enrollment

  10. iPrEx HIV protection 100 infections after randomization 36 on FTC/TDF 64 on placebo Efficacy estimate (mITT): 44% reduction in HIV acquisition (95% CI 15%-63%) Weeks on Study 2 cases of M184V resistance in participants in “window period” at time of PrEP initiation = avoid PrEP initiation in those who have acute HIV infection

  11. 4758 HIV serodiscordant couples (HIV+ partner not yet medically eligible for ART) Randomize HIV- partners (normal liver, renal, hematologic function) TDF once daily FTC/TDF once daily Placebo once daily Follow couples for up to 36 months 1° endpoint: HIV infection in HIV- partner Co- 1° endpoint: Safety Partners PrEP Study All receiving comprehensiveHIV prevention services

  12. Slides presented IAS 2011 Primary efficacy results • Primary analysis: modified intention-to-treat (mITT) • excluding infections present at randomization (3 TDF, 3 FTC/TDF, 6 placebo) Effect of TDF and FTC/TDF statistically similar (p=0.18) ITT analysis results similar

  13. Slides presented IAS 2011 Subgroup analysis - gender • Both TDF and FTC/TDF significantly reduced HIV risk in both men and women Women: 42 total infections: 8 TDF, 9 FTC/TDF, 25 placebo Men: 36 infections: 10 TDF, 4 FTC/TDF, 22 placebo

  14. Slides presented IAS 2011 Safety • No statistically significant difference in deaths, SAEs, key laboratory AEs

  15. Some disappointments though…….

  16. Ongoing safety and effectiveness study of tenofovir gel, oral TDF, and oral FTC/TDF for prevention of HIV

  17. Ongoing safety and effectiveness study of tenofovir gel, oral TDF, and oral FTC/TDF for prevention of HIV

  18. Ongoing safety and effectiveness study of tenofovir gel, oral TDF, and oral FTC/TDF for prevention of HIV

  19. A word of caution………..

  20. CAPRISA 004 & iPrEx: PrEP is all about adherence CAPRISA 004 • High (>80% gel adherence)n=336 (38%) 54% effective • Low (<50% gel adherence)n=367 (42%) 28% effective iPrEx • 8% of seroconverters had detectable drug at first HIV+ visit (and only 54% of nonseroconverters)  92% estimated efficacy if drug was present

  21. Combination HIV prevention: a package • What works for HIV prevention: • Male circumcision (FM risk) • Male condoms, female condoms (probably) • Counseling and testing, particularly as a couple (probably) • ↓ partner #, delayed sexual debut, abstinence • Treatment of STIs (probably best to decrease infectiousness in HIV+s) • Conditional cash transfer • ART • Oral/topical PrEP • ? Vaccine • Multiple, integrated, biomedical and behavioral interventions Combination prevention. Coates, et al. Lancet 2009

  22. ACKNOWLEDGEMENT • Adaora A. Adimora • Audrey Pettifor • Dannielle Haley • Jessica Justman • Mara Nakagawa-Harwood • Jaread Baeten • Connie Celum • Pedro Cahn • Julio Montaner • And many others behind the scene

More Related